| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-642 | |
| Phytochemical name or plant extracts | Glyceollin | |
| PMID | 11297613 | |
| Literature evidence | The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their estrogenic activity as well as their effects on human health and disease. | |
| IUPAC name | (2S,10S)-17,17-dimethyl-3,12,18-trioxapentacyclo[11.8.0.02,10.04,9.014,19]henicosa-1(13),4(9),5,7,14(19),15,20-heptaene-6,10-diol | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Glycine max | |
| Geographical availability | Amur, China North-Central, China South-Central, China Southeast, Hainan, Inner Mongolia, Japan, Khabarovsk, Korea, Laos, Manchuria, Nansei-shoto, Primorye, Qinghai, Taiwan, Thailand, Tibet, Vietnam, Xinjiang | |
| Plant parts | Seeds | |
| Other cancers | Breast cancer | |
| Target gene or protein | NGFR | |
| Gene or Protein evidence | Glyceollin caused a 3.29-fold increase in NGFR, whereas tamoxifen and estrogen treatments did not cause a significant change in expression. | |
| Target pathways | ER signaling | |
| IC50 | 3.2μ mol/L for ERα 6.4 μmol/L for ERβ | |
| Potency | Glyceollins trigger anti-proliferative effects through estradiol-dependent and independent pathways in breast cancer cells. These results reinforce the therapeutic potential of glyceollins for breast cancer. | |
| Cell line/ mice model | HEK 293, MCF-7,nu/nu immune-compromised female ovariectomized mice, BG-1 | |
| Additional information | Before large-scale glyceollin production is achieved, glyceollin-included soybean products could be used for clinical trials on preventing breast cancer and some other related diseases. | |
| PubChem ID | 162807 | |
| Additional PMIDs | 28666461 38034638 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60450240-2 | |
| Safety | NA |